Clearance of IND application received from the U.S. FDA Planned Phase 1/2 outpatient clinical trial will focus on patients with early SARS-CoV-2 infection Placebo-controlled trial expected to commence in June with data readout expected in Q4 2020 Therapeutic development program will complement

GAITHERSBURG, Md. , May 13, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the quarter ended March 31, 2020 and provided a business update. “Throughout 2020 we have put significant effort into developing our

GAITHERSBURG, Md. , May 12, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced the appointment of Diane Jorkasky , M.D. to its Board of Directors. With Dr. Jorkasky’s appointment, the size of the board increased to eight members.

GAITHERSBURG, Md. , May 08, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report financial results for the first quarter ended March 31, 2020 before the market open and host a conference call on Thursday, May 14,

GAITHERSBURG, Md. , March 30, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it is launching a collaboration with the University of Alabama at Birmingham (UAB) on the development of its single-dose, intranasal COVID-19

Conference Call & Webcast Scheduled for Friday, March 27, at 8:30 am Eastern Time GAITHERSBURG, Md. , March 27, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the year ended December 31, 2019 and provided a

GAITHERSBURG, Md. , March 25, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report financial results for the year ended December 31, 2019 and host a conference call on Friday, March 27, 2020 .

GAITHERSBURG, Md. , Feb. 28, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced the advancement of a novel single-dose, intranasal vaccine using Altimmune’s proprietary technology to protect against COVID-19, the disease caused by the

GAITHERSBURG, Md. , Feb. 19, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Vipin K. Garg , Ph.D., President and Chief Executive Officer will present at the Cowen 40 th Annual Health Care Conference in Boston on Monday, March

GAITHERSBURG, Md. , Feb. 04, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that management will present at the following conferences during the months of February:     2020 BIO CEO & Investor Conference Date:    Monday, February